

Delete the current Sequence Listing located at the end of the application and replace it with the new Sequence Listing submitted herewith.

REMARKS


Applicants amend the specification to accurately describe the sequence shown in Figure 10 and provide clean and marked-up versions of the amended paragraph. In addition, a new Sequence Listing is provided that clarifies the description of SEQ ID NOS:13, 14, 47, and 49. Support for these amendments may be found in the specification, for example, on page 33, line 29, page 35, line 27, page 44, lines 18-25, and page 47, lines 13-17. No new matter has been added by these amendments.

CONCLUSION

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 11 October 2001


James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110-2214
Telephone: 617-428-0200
Facsimile: 617-428-7045

50026.027001--Preliminary Amendment Correcting Sequence Listing.dot



21559

PATENT TRADEMARK OFFICE

Clean Version of the Amended Paragraph

Figure 10 shows a comparison of nucleotide sequence between mouse (SEQ ID NO:3) and human (SEQ ID NO:5) "Tespec PRO-2". The nucleotides conserved between the two are boxed.

Version with Markings to Show Changes Made

Replace the paragraph beginning on page 32, line 22, with the following paragraph.

--Figure 10 shows a comparison of [amino acid] nucleotide sequence between mouse (SEQ ID NO:3) and human (SEQ ID NO:5) "Tespec PRO-2". The nucleotides conserved between the two are boxed.--

Certificate of Mailing: Date of Deposit: October 11, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Elaine Fabrizio

Printed name of person mailing correspondence

Elaine Fabrizio

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chiaki Senoo et al.

Art Unit:

Serial No.: 09/831,180

Examiner:

Filed: May 3, 2001

Customer No.: 21559

Title: NOVEL TRYPSIN FAMILY SERINE PROTEASES

Assistant Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.825

Enclosed is an amended Sequence Listing, in accordance with 37 C.F.R. § 1.825(a), consisting of 25 sheets to be inserted at the end of the application. The amended Sequence Listing submitted herewith replaces the current Sequence Listing enclosed with the Reply to the Notification to Comply with Sequence Requirements mailed on August 3, 2001.

As is stated in the accompanying Preliminary Amendment, the Sequence Listing has been amended to clarify the description of SEQ ID NOS:13, 14, 47, and 49. Support for these amendments may be found in the specification, for example, on page 33, line 29, page 35, line 27, page 44, lines 18-25, and page 47, lines 13-17. I hereby submit that the


substitute sheets contain no new matter.

As required by 37 C.F.R. § 1.825(b), enclosed is a diskette containing a copy of the sequence listing in computer readable form including all previously submitted data with the amendments incorporated therein. The contents of the computer readable form are the same as the contents of the paper sheets.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 11 October 2001



James D. DeCamp Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
50026.027001 Sequence Statement.wpd



21559

PATENT TRADEMARK OFFICE